ライフサイエンスコーパス: left ventricular dilation

1 or progressive symptomatic heart failure and left ventricular dilation.

2 aortic regurgitation complicated by extreme left ventricular dilation.

3 The phenotype consisted of left ventricular dilation (68%), systolic dysfunction (4

4 tration of an MMP inhibitor attenuates early left ventricular dilation after experimental MI in mice.

5 ensitized mice to cardiac decompensation and left ventricular dilation after long-term stimulation by

6 Cardiac rupture is preceded by left ventricular dilation and a severe decrease in cardi

7 raphic analysis demonstrated the presence of left ventricular dilation and decreased systolic functio

8 ondrial CaMKII inhibition are protected from left ventricular dilation and dysfunction after MI.

9 cision Medicine Study included patients with left ventricular dilation and dysfunction attributed to

10 farction with 3 months follow-up resulted in left ventricular dilation and dysfunction in both wild-t

11 scription and angiogenesis, thereby limiting left ventricular dilation and dysfunction.

12 nosine receptor (AR) pathways in hearts with left ventricular dilation and dysfunction.

13 ressure 85+/-1 versus 66+/-2 mm Hg; P<0.01), left ventricular dilation and hypertrophy (mass/body wei

14 inst adverse functional consequences of TAC, left ventricular dilation and impaired ejection fraction

15 Mutant G202R and A592E mice exhibited left ventricular dilation and impaired function with spe

16 fold more than wild type, along with greater left ventricular dilation and increased fibrosis, apopto

17 by day 14, echocardiography showed increased left ventricular dilation and infarct expansion.

18 r changes were associated with reductions in left ventricular dilation and left ventricular mass meas

19 Left ventricular dilation and loss of heart function was

20 asis during atrial arrhythmia are those with left ventricular dilation and low atrial ejection fracti

21 initially with an epicardial patch to limit left ventricular dilation and mitral regurgitation.

22 ion < 3+, fibrillation (vs. type I flutter), left ventricular dilation and mitral valve area < 2.0 cm

23 Left ventricular dilation and myocardial fibrosis are as

24 Thallium lung-to-myocardial ratio (L/M), left ventricular dilation and perfusion defect site were

25 Lung uptake, left ventricular dilation and perfusion defect size show

26 In mice with left ventricular dilation and pump failure attributable

27 ardiography of homozygous mutant mice showed left ventricular dilation and reduced contractile functi

28 isolated myocytes was depressed and preceded left ventricular dilation and reduced fractional shorten

29 may also enhance late survival by preventing left ventricular dilation and reducing arrhythmias, inde

30 trials of afterload reduction for preventing left ventricular dilation and symptom onset in aortic re

31 Dilated cardiomyopathy, characterized by left ventricular dilation and systolic dysfunction with

32 Left ventricular dilation and the presence of late gadol

33 Heterozygous patients exhibit left ventricular dilation and ventricular arrhythmias.

34 e-dependent increase in cardiac hypertrophy, left ventricular dilation, and adverse left ventricular

35 ry hypertrophy of unaffected cardiomyocytes, left ventricular dilation, and impaired contractile func

36 eft ventricular ejection fraction <40%, mild left ventricular dilation, and no symptoms of heart fail

37 also developed greater cardiac hypertrophy, left ventricular dilation, and reduced contractile funct

38 higher rates of cardiac rupture, more severe left ventricular dilation, and suppressed ejection fract

39 ly and late activated regions and (2) Global left ventricular dilation as measured in experiments.

40 ith vascular-specific expression (vGOF) show left ventricular dilation as well as less-markedly incre

41 with db/db animals, dbTSP mice had increased left ventricular dilation associated with mild nonprogre

42 Untreated sheep developed left ventricular dilation at 3 months, with global dysfu

43 r age, congestive heart failure, and greater left ventricular dilation at diagnosis were independentl

44 ce could not be attributed to differences in left ventricular dilation because end-diastolic volumes

45 Both NOS inhibitors led to left ventricular dilation, but PE did not.

46 -)) mice, loss of cMyBP-C has been linked to left ventricular dilation, cardiac hypertrophy, and syst

47 Results: Pressure overload evoked rapid left ventricular dilation compared with sham (end-systol

48 favored an increase in myocyte width without left ventricular dilation (concentric hypertrophy) and p

49 ddle age, heterozygous individuals developed left ventricular dilation, contractile dysfunction, and

50 ed a decline in cardiac function, attenuated left ventricular dilation, decreased infarct size, and r

51 e was exacerbated, as indicated by increased left ventricular dilation, decreased ventricular functio

52 e with adverse outcomes are characterized by left ventricular dilation despite CRT.

53 mmended in aortic regurgitation with extreme left ventricular dilation (diastolic dimension >/= 80 mm

54 Extreme left ventricular dilation due to aortic regurgitation is

55 tic regurgitation (AR) focus on symptoms and left ventricular dilation/dysfunction.

56 ture (40% higher after 30 days) and stronger left ventricular dilation early after MI.

57 ning, 28.4% versus 18.8%; P=0.0114), reduced left ventricular dilation (end-systolic inner left ventr

58 C, C4KOs developed severe heart failure with left ventricular dilation, impaired cardiomyocyte growth

59 on, worsened systolic dysfunction, increased left ventricular dilation, impaired scar maturation, and

60 Trpc6 deletion also ameliorated left ventricular dilation, improved cardiac function, an

61 cal heart failure therapy indexed by reduced left ventricular dilation, improved left ventricular eje

62 phy up to day 56 after MI revealed increased left ventricular dilation in CD4 KO compared with WT mic

63 onstriction (TAC) for 6 weeks caused greater left ventricular dilation in G6PDX mice than wild-type m

64 ocardiography showed significantly increased left ventricular dilation in male IL-13(-/-) compared wi

65 calmodulin kinase II (CaMKII) activation and left ventricular dilation in mice one week after myocard

66 cardiography at day 1 demonstrated increased left ventricular dilation in OIM/OIM animals.

67 Therefore, extreme left ventricular dilation is not a contraindication to o

68 aled severe cardiac abnormalities, including left ventricular dilation, left ventricular mass reducti

69 Left ventricular dilation may predispose to alterations

70 al regurgitation is indicated if symptoms or left ventricular dilation or dysfunction occur.

71 It can be associated with left ventricular dilation or hypertrophy, systolic or di

72 eft, P < 0.0001; right, P = 0.0037) and less left ventricular dilation (P < 0.0179).

73 entricular ejection fraction (p = 0.006) and left ventricular dilation (p = 0.015) at the follow-up e

74 iac disease, there was weak correlation with left ventricular dilation (r = 0.423, p = 0.020) but not

75 (diastolic dimension >/= 80 mm), but extreme left ventricular dilation raises concern about irreversi

76 Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systol

77 ed a rapidly progressive cardiomyopathy with left ventricular dilation, wall thinning, and reduced sy

78 Left ventricular dilation was associated with hemodynami

79 Left ventricular dilation was reduced in the GH-treated

80 Preoperatively, extreme left ventricular dilation was seen only in male patients

81 ardial infarction (MI) developed progressive left ventricular dilation with dysfunction and HF at 4 w

82 can potentially induce a reversible form of left ventricular dilation with systolic dysfunction, kno